Sentence examples for of human activated from inspiring English sources
These results suggest that mitochondrial uncoupling cannot only reduce culture induced activation of mouse HSCs, but also reduces the fibrogenic phenotype of human activated HSCs.
In addition, we performed duplicates of FoxP3 ChIP-Seq experiments (FoxP3 antibody-mediated chromatin immunoprecipitation followed by Illumina sequencing of DNA fragments) of human activated Th cells and nTregs.
Previous studies have shown that potassium channels can regulate the cytokine secretion of human activated macrophages [ 23].
Wistar rats inoculated with different numbers of human activated PBMC were selected as the animal model of choice.
As IL-13R α2 protein expression was negative in normal human tissues as examined by IHC in human tissue array (Fig. S2), and IL-13R α2 gene expression was also undetected in 14 cases of human activated lymphocytes (with IL-2) and 21 cases of blood lymphocytes (data not shown), it is unlikely that the toxicities exhibited in Pt.7 and Pt.8 were due to off-target effect of IL-13-PE.
Drotrecogin alfa-activated is a recombinant form of human activated protein C (rhAPC), i.e. it is a protein produced by recombinant DNA.
By using P-selectin conjugated USPIO, Jacobin Valat et al. demonstrated the expression of P-selectin on human activated platelets involved in the early stages of atherosclerosis [11].
Quantification of various cytokines in macrophage cell supernatants indicates that the addition of RU to human activated macrophages significantly (p < 0.02) decreased the concentrations of TNF-α, IL-1β, and IL-6, three critical proinflammatory cytokines.
APC: activated protein C. SPL is a former employee of Eli Lilly and company, the maker of recombinant human activated Protein C.
It similarly imparts decreased binding to the 131R allele of human activating FcγR, CD32A (KD: from 36 nM to 218 nM), but binding to the 131H allele is not substantially modified (KD: from 39 nM to 34 nM).
Significant attention was also given to staffing level, optimization of intensive care unit capacity, and drug cost-effectiveness, particularly that of recombinant human activated protein C. Managing costs and providing high-quality care simultaneously are emerging challenges that we must understand and meet.
